CareDx's Transformation: From Transplant Diagnostics to Precision Oncology

NavDx acquisition and LCD finalization fuel a 200% rally as the company repositions for growth.

CDNA · Earnings Call · 2026-07-30

From Transplant to Oncology: A Pivot Accelerates

CareDx has long been the dominant player in transplant diagnostics, but the story this quarter is a deliberate and swift expansion into specialty oncology. On the Q2 2026 call, CEO John Hanna opened with a declaration that set the tone:

Two years ago, we set out to transform CareDx into a leading precision medicine diagnostics company. Today, that transformation is largely complete.
John Hanna, Chief Executive Officer · 2026-07-30

The most tangible evidence is the July 1 close of the NavDx acquisition, which adds a circulating tumor HPV DNA platform for head and neck and anal cancers — a market the company estimates at a multi-billion-dollar TAM. This is not a peripheral tuck-in; management explicitly stated the model is repeatable: “The CareDx model is built on longitudinal molecular testing that informs clinical decision-making, supported by robust clinical evidence, integrated workflows, and patient engagement.” — John Hanna, Chief Executive Officer · 2026-07-30 The strategic pivot is also reflected in the pipeline. AlloHeme, a recurrence-monitoring test for cell-therapy patients, is on track for CLIA readiness by year-end and a 2027 commercial launch. Meanwhile, HistoMap kidney moves into a clinical study this year, with data showing it can stratify graft-loss risk more than threefold — a powerful complement to the existing AlloSure blood test. These are not incremental line extensions; they represent an intentional broadening of the precision medicine franchise.

The Evidence Engine and LCD Tailwind

The company’s core transplant business also gained a critical catalyst: the finalization of the Medicare local coverage determination (LCD) for solid organ transplant molecular testing. John Hanna emphasized the dual benefit: “The policy affirms coverage for surveillance testing across kidney, heart, and lung transplant and reinforces the role of AlloSure and AlloMap in post-transplant patient management.” — John Hanna, Chief Executive Officer · 2026-07-30 Crucially, it also establishes a reimbursement pathway for HistoMap, a key de-risk for the next launch. This removes a long-standing overhang. Only a few quarters earlier, management was still deferring 2026 guidance pending LCD clarity: “We're going to defer any discussion on 2026 until after the clarity on the LCD,” — Tycho Peterson, Analyst · 2025-11-04 said John Hanna in November 2025. The company had been modeling a $7.5 million headwind from the draft policy; today, that has been removed entirely. The final policy not only protects existing revenue but also legitimizes the entire molecular surveillance paradigm, as reflected in the strong surveillance testing volume growth. Clinical data continues to differentiate the platform. At ATC and in the JASN publication, new analyses demonstrated that persistently elevated AlloSure levels are associated with up to a nine-fold higher risk of graft loss — evidence that cements AlloSure’s role as a trajectory-based tool, not just a single biomarker. This evidence engine is also being applied to the new oncology franchise, with a 40,000-patient cohort presented at the head-and-neck meeting supporting NavDx’s ability to predict response to salvage therapy.

Financial Inflection Point

The financial results underscore the momentum. Q2 revenue rose 52% year-over-year to $132 million, with testing services up 61% to $100 million. CFO Keith Kennedy detailed the outperformance: “Total revenue increased 52% to $132 million. Testing services revenue increased 61% to $100 million or $1,720 per test.” — Keith Kennedy, Chief Financial Officer · 2026-07-30 Non-GAAP gross margins expanded to 74%, and adjusted EBITDA reached $25 million, a $19 million year-over-year improvement. The company raised full-year revenue guidance to $490–500 million, representing 30% growth at the midpoint — notably, this excludes any contribution from the NavDx acquisition beyond the second half. Total revenue has inflected sharply, with the 52% growth accelerating from the 39% year-over-year pace reported just one quarter earlier. The balance sheet also provides strategic flexibility – $374 million in cash and no debt, after divesting the lab products business at a $113 million gain. The stock has responded emphatically, rallying more than 200% over the past 90 days. This is not just a beta move; it reflects a fundamental rewriting of the growth algorithm. The company has moved from a single-market transplant test provider to a multi-market precision diagnostics platform, with the NavDx acquisition giving it a beachhead in a fast-growing oncology indication. As management reiterated, the long-term margin target is 20% EBITDA, and with the LCD risk resolved and the oncology ramp just beginning, the market is starting to price in that trajectory. What changed? Everything about the future addressable market. CareDx now has a differentiated MRD asset, a clear runway for HistoMap, and a validated reimbursement base — a combination that fundamentally alters the risk-reward for a company that was, just two years ago, wrestling with payer pressure and transplant volume stagnation. The transformation John Hanna described is not just rhetorical; it is visible in the numbers, the pipeline, and the stock.